Abstract: The present invention is a solution for preservation of organs prior to organ transplantation used in reducing the damage occurring during transportation and waiting of liver and kidney prior to transplantation. Accordingly, the subject matter solution is characterized by comprising Raffinose in the range of 25-35 mmol/L, Lactobionate in the range of 80-120 mmol/L, HES (Hydroxy-ethyl starch) in the range of 0-4% g, SO42? in the range of 4.5-5.5 mmol/L, Adenosine in the range of 4.5-5.5 mmol/L, Glutathione in the range of 2.7-3.3 mmol/L, Allopurinol in the range of 0.9-1.1 mmol/l, Na+ in the range of 27-33 mmol/L, K+ in the range of 115-125 mmol/L, Mg+ in the range of 4.5-5.5 mmol/L, Histidine/Histidine-HCl in the range of (25-30)/(2.5-3.0) mmol/L, Melatonin in the range of 30-50 mg/L, Glucosamine in the range of 20-100 mg/L.

Abstract: Described is a method of inhibiting central apnea, central hypopnea or obstructive sleep apnea in a mammal. The method includes the step of administering to a mammal a central apnea inhibitory-effective, central hypopnea inhibitory-effective or obstructive sleep apnea inhibitory-effective amount of a composition comprising at least one retinoid or retinoid or retinoic acid receptor agonist.

Abstract: In one aspect, methods of biomolecular analysis are described herein. Briefly, a method comprises providing a composition comprising glycosaminoglycans and contacting the composition with a membrane comprising at least one nanopore. An electric field is applied across the nanopore, and data of glycosaminoglycan translocation events through the nanopore are recorded. A molecular weight distribution of the glycosaminoglycans is derived from the data.

Abstract: A composition and method for using it to prevent and/or relieve symptoms of acute respiratory tract infections, particularly bronchitis, in immune-compromised persons, particularly adults. The composition contains 2?-fucosyllactose and lacto-N-neotetraose and/or lacto-N-tetraose.

Abstract: A lipid layer forming composition comprises a volatile silicone oil of a boiling point above 180° C., a polar lipid, optionally a C2-C4 aliphatic alcohol, optionally a pharmacologically or cosmetically active agent or a protective agent. The lipid layer forming composition can be applied to a biological surface by spraying, dipping or brushing to form a stable polar lipid layer on the surface.

Abstract: A lipid layer forming composition comprises a volatile silicone oil of a boiling point above 180° C., a polar lipid, optionally a C2-C4 aliphatic alcohol, optionally a pharmacologically or cosmetically active agent or a protective agent. The lipid layer forming composition can be applied to a biological surface by spraying, dipping or brushing to form a stable polar lipid layer on the surface.

Abstract: Embodiments of the present inventions comprise composites of polyurethane(s), osteoconductive matrix, and, optionally, a growth factor. Embodiments further comprise methods of making such composite and uses thereof. The osteoconductive matrix can be a tricalcium phosphate, bioglass, or the like, and can include particles that are surface modified. Growth factors can be provided in powder form, including bone morphogenic proteins such as rhBMP-2. A composition may be moldable and/or injectable. After implantation or injection, a composition may be set to form a porous composite that provides mechanical strength and supports the in-growth of cells.

Abstract: An aqueous patch containing diclofenac sodium, wherein the patch contains a homogeneous mixed solution of diclofenac sodium, wherein the solution is obtained by mixing crotamiton, diclofenac sodium and water in the mixture ratio of crotamiton/diclofenac sodium of 8.0 or less and the mixture ratio of (water+crotamiton)/diclofenac sodium of 3.0-20.0.

Abstract: A method of producing a protein or polypeptide, such as, for example, TSG-6 protein, or a biologically active fragment, derivative or analogue thereof, by introducing into mammalian cells a polynucleotide encoding the biologically active protein or polypeptide or biologically active fragment, derivative, or analogue thereof. The cells then are suspended in a protein-free medium that includes at least one agent that suppresses production of hyaluronic acid, hyaluronan, or a salt thereof by the cells. The cells are cultured for a time sufficient to express the biologically active protein or polypeptide or biologically active fragment, derivative or analogue thereof. The biologically active protein or polypeptide, or fragment, derivative, or analogue thereof then is recovered from the cells, such as, for example, by recovering the protein or polypeptide secreted by the cells from the cell culture medium.

Abstract: The present invention relates to novel cytotoxic molecules and their use for the treatment of cancer and other diseases.

Abstract: The present invention relates to an agent for improving lipid metabolism, a food/drink, and a feed, containing ?s-casein as an active ingredient thereof. In addition, the present invention relates to an agent for suppressing body weight gain, an agent for reducing body fat, and an agent for reducing blood lipid, containing the agent for improving lipid metabolism.

Abstract: The invention comprises a composition comprising a bioerodible porous silicon-based carrier material wherein the carrier material carries at least one large molecule therapeutic agent and at least one amorphous sugar, optionally further comprising a crystallization inhibitor. The composition may be used in vitro or in vivo to deliver the therapeutic agent, preferably in a controlled fashion over an intended period of time such as over multiple days, weeks or months. The composition may be used for treating or preventing conditions of a patient such as chronic diseases.

Abstract: For an implantable device intended for use in the human body an in-vivo colonization with autologous cells is often desired. The devices, especially prosthetic devices like implant tissues, grafts, shunts, vessels, organs or a part of organs are commonly derived from animal or human origin and comprise a collagen-based tissue matrix. The invention proposes a coating deposited on a surface of the device and comprising the matrix protein CCN1 as an extracellular matrix-associated protein mediating cell adhesion or cell migration.

Abstract: A method for purifying bone-derived osteoinductive proteins including a demineralization process, a protein extraction process, a high molecular weight ultrafiltration process, a low molecular weight ultrafiltration process, and a recover process. The high and low ultrafiltration processes preferably select proteins having a nominal molecular weight between approximately 8 kilodaltons and approximately 100 kilodaltons. Processes of the present invention may be used to recover osteoinductive proteins from bone demineralization waste streams.

Abstract: A composition for preventing and treating fatty liver is disclosed. The composition includes a lactoferrin and a trivalent chromium compound. The trivalent chromium compound of the present invention is selected from the group consisting of chromium (III) chloride hexahydrate, chromium (III) chloride, chromium (III) acetate, chromium (III) sulfate, chromium picolinate, chromium nicotinate, chromium GTF, chromium yeast extract, other inorganic salts of trivalent chromium, other organic salts of trivalent chromium, and combinations thereof. The composition of the present invention can provide a beneficial effect in preventing and treating fatty liver by effectively reducing multiple risk factors of fatty liver disease.

Abstract: Disclosed are compositions comprising isolated peptides having a leucine content of from about 12 to about 40 weight percent. Also disclosed is a method for isolating leucine-rich peptides from protein sources such as bovine whey and methods of use for these peptides to provide beneficial effects in a human and/or animal such as increasing blood flow, decreasing blood pressure, increasing muscle mass, improving cognitive function, improving cardiovascular function, etc.

Abstract: The invention relates to methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid (3APS) in a subject, preferably a human subject. The invention encompasses compounds that will yield or generate 3APS, either in vitro or in vivo. Preferred compounds include amino acid prodrugs of 3APS for use, including but not limited to, the prevention and treatment of Alzheimer's disease.

Abstract: The current invention is directed to methods of inducing migration of an immune cell toward a cancer cell comprising inhibiting the activity of a chemorepellant released from the cancer cell.

Abstract: The present invention relates to pharmaceutical compositions, food supplement compositions and cosmetic compositions comprising diaminooxidase, and to the use thereof.

Abstract: Disclosed herein are ?7?1 integrin modulatory agents and methods of using such to treat conditions associated with decreased ?7?1 integrin expression or activity, including muscular dystrophy. In one example, methods for treating a subject with muscular dystrophy are disclosed. The methods include administering an effective amount of an ?7?1 integrin modulatory agent to the subject with muscular dystrophy, wherein the ?7?1 integrin modulatory agent increases ?7?1 integrin expression or activity as compared to ?7?1 integrin expression or activity prior to treatment, thereby treating the subject with muscular dystrophy. Also disclosed are methods of enhancing muscle regeneration, repair, or maintenance in a subject and methods of enhancing ?7?1 integrin expression by use of the disclosed ?7?1 integrin modulatory agents. Methods of prospectively preventing or reducing muscle injury or damage in a subject are also disclosed.

Abstract: Methods for reducing the severity of an arthritic condition or repairing an osteochondral defect are carried out by administering to a subject compositions comprising a member of the matrilin family of proteins, e.g., a matrilin protein, fragment thereof, or nucleic acid encoding the protein or fragment.

Abstract: Hydrolyzed collagen type II powder compositions for inducing cartilage formation in an individual, method of preparing the compositions and use of the compositions in treating connective tissue disorder, replenishing skin viscoelasticity. The compositions are administered through an orally ingestible delivery medium for absorption into the gastrointestinal tract. The compositions are administered through a topical delivery medium for absorption into a dermis of the individual.

Abstract: Provided herein are keratin compositions useful for treating ischemia and/or reperfusion injury, such as that associated with myocardial infarct, ischemic stroke, brain trauma such as traumatic brain injury, hypothermia, chronic wounds, and burns.

Abstract: The present invention relates to granulocyte colony stimulating factor (G-CSF) modified with Y-shaped branched polyethylene glycol (YPEG-G-CSF) at a specific lysine (Lys 17) and the preparation thereof, as well as the pharmaceutical composition comprising YPEG-G-CSF and use thereof.

Abstract: An ionic complex precipitate comprising a hedgehog protein and deoxycholate whereby the forming of the complex does not enhance the solubility of said protein, is suitable for increasing the activity of the protein and/or for the delayed release of the protein.

Abstract: Various cells, stem cells, and stem cell components, including associated methods of generating and using such cells are provided. In one aspect, for example, an isolated cell that is capable of self-renewal and culture expansion and is obtained from a subepithelial layer of a mammalian umbilical cord tissue. Such an isolated cell expresses at least three cell markers selected from CD29, CD73, CD90, CD166, SSEA4, CD9, CD44, CD146, or CD105, and does not express at least three cell markers selected from CD45, CD34, CD14, CD79, CD106, CD86, CD80, CD19, CD117, Stro-1, or HLA-DR.

Abstract: A new method for krill meal production has been developed using a two step cooking process. In the first step the proteins and phospholipids are removed from the krill and precipitated as a coagulum. In the second stage the krill without phospholipids are cooked. Following this, residual fat and astaxanthin are removed from the krill using mechanical separation methods. A novel krill meal product with superior nutritional and technical properties is prepared.

Abstract: Novel methods for biological effective, stable amorphous and monoclinic selenium nanoparticles are disclosed. They are prepared by reacting selenium source with a reducing agent or an oxidative agent in an aqueous media at a temperature between 0-100° C. in the presence of selenium binding polymer molecules such as poly/oligopeptide acids or peptone or nucleic acids or poly/oligosaccharide or their mixtures.

Abstract: Prepared is an extract composition having an improved protein synthetic activity in a cell-free protein synthesis system using a mammalian cultured cell extract. An eukaryotic translation initiation factor and/or translational regulator are added to a cell-free protein synthesis system comprising an extract prepared from cultured mammalian cells and a template mRNA. These factors are one or more selected from the group consisting of eukaryotic translation initiation factors 4E (eIF4E), 2 (eIF2) and 2B (eIF2B), and eukaryotic translational regulator p97.

Abstract: The present invention relates to biocompatible, biodegradable polyurethane/urea polymeric compositions that are capable of in-vivo curing with low heat generation to form materials suitable for use in scaffolds in tissue engineering applications such as bone and cartilage repair. The polymers are desirably flowable and injectable and can support living biological components to aid in the healing process. They may be cured ex-vivo for invasive surgical repair methods, or alternatively utilized for relatively non-invasive surgical repair methods such as by arthroscope. The invention also relates to prepolymers useful in the preparation of the polymeric compositions, and to methods of treatment of damaged tissue using the polymers of the invention.

Abstract: Hydrogel compositions comprise an aqueous dispersion phase and a plurality of peptides, or derivatives, or analogues thereof. Each peptide comprises at least two amino acid residues and an aromatic stacking ligand and the hydrogel is formed by self-assembly of said peptides in said aqueous dispersion medium. The aqueous dispersion phase is physiologically acceptable and may have a pH of 6 to 8, as may the hydrogel itself. The hydrogel may be used for cell culture or for treatment of medical conditions characterized by tissue loss/damage.

Abstract: A kit for forming a biocompatible material provides a protein solution and a polymer solution including a derivative of a hydrophilic polymer with a functionality of at least three. Upon mixing. the protein solution and the polymer solution cross-link to form a non-liquid, three-dimensional network that degrades over time back to a liquid form. The polymer includes a degradation control region selected to achieve a desired degradation period and a cross-linking group selected to achieve a desired cross-linking period. The kit provides instructions for forming a mixture of the protein solution and polymer solution and for applying the mixture. The mixture serves as the foundation for multiple material composition species, each adapted to a specific therapeutic indication.

Abstract: To provide a method of reducing an intrinsic harsh/astringent taste of protamine and a protamine salt and effectively using a fat absorption suppressive effect of these. A complex is formed by reacting at least one of acidic macromolecular substances, such as alginate and polyglutamate, and gum arabic which are capable of forming a complex reducing harsh/astringent taste and dissociating protamine having a lipase inhibitory activity by pepsin treatment, with protamine or a protamine salt.

Abstract: A method mixes a first component, a second component, and a buffer material. The first component includes an electrophilic polymer material comprising poly(ethylene glycol) having a functionality of at least three. The second component includes a nucleophilic material comprising a natural or synthetic protein at a concentration of about 25% or less that, when mixed with the first component within a reaction pH range, cross-links with the first component to form a non-liquid, three-dimensional barrier. The buffer material includes tris-hydroxymethylaminomethane having a pH within the reaction pH range. The method applies the mixture to adhere to a tissue region.

Abstract: The instant invention comprises a process for the solid phase synthesis of directed epitope peptide mixtures useful in the modulation of unwanted immune responses, such process defined by a set of rules regarding the identity and the frequency of occurrence of amino acids that substitute a base or native amino acid of a known epitope. The resulting composition is a mixture of related peptides for therapeutic use.

Abstract: A new method for krill meal production has been developed using a two step cooking process. In the first step the proteins and phospholipids are removed from the krill and precipitated as a coagulum. In the second stage the krill without phospholipids are cooked. Following this, residual fat and astaxanthin are removed from the krill using mechanical separation methods. A novel krill meal product with superior nutritional and technical properties is prepared.

Abstract: The invention discloses a new solvent-free process for obtaining phospholipids and neutral lipids enriched krill oils containing DHA and EPA poly-unsaturated fatty acids and astaxanthin. The process includes cooking fresh krill at high temperature-without agitation and or grinding; decanting the cooked krill for obtaining a partial de-fatted and de-watered solid and a liquid; squeezing the obtained solid to obtain a press liquid and a solid fraction; centrifuging the press liquid to obtain the phospholipids enriched krill oil; centrifuging of the decanter liquid obtained to obtain the neutral lipid enriched krill oil and stickwater.

Abstract: The inventive compositions comprise in a deionized water base, a composition comprising: a preservative, a chelating agent; one or more moisturizer and hydrolyzed keratin protein; an antioxidant selected from the group consisting of citric acid and a vitamin E salt; and an emulsifier-water trap selected from the group consisting of cetearyl alcohol and glyceryl stearate; and PEG-40 castor oil. The composition, which is in liquid form, may be applied in the form of a spray or mist by dipping the affected area in the liquid or by pouring a small amount of the liquid onto the hair or body to be treated.

Abstract: Methods of diagnosing or prognosing a disease or condition associated with increased or over expression of macrophage inhibitory cytokine-1 (MIC-1) are disclosed. The methods typically involve detecting a change in the amount of MIC-1 in a test body sample from a subject taken at two or more timing points. The change in the amount of MIC-1 may be adjusted for the effect of at least the following factors as appropriate: the gender of the subject, the age of the subject, the body mass index (BMI) of the subject, the subject being a smoker, the subject being a user of NSAIDs, and the waist-to-hip ratio where the subject is female. The methods are particularly suitable for diagnosing or prognosing the presence of one or more colorectal polyp(s).

Abstract: Pharmaceutical, dental and/or cosmetic composition consisting of purified Enamel Matrix Derivative (EMD) proteins which have a molecular weight between 1 and 55 kDa, formulated in a suitable pharmaceutical carrier. The composition is depleted of proteins which have a molecular weight between 56 and 160 kDa and an iso-electric point between 3-10. The purified Enamel Matrix Derivative (EMD) proteins are depleted of proteinase inhibitors, such as ?1-antichymotrypsin and/or Fetuin A. The composition is preferably used for promoting and/or inducing regeneration of hard tissue, tissue mineralization, bone growth and/or bone regrowth, regeneration of dentin, cementogenesis, and/or binding between parts of living mineralized tissue, for bonding of a piece of living mineralized tissue to a bonding site on a piece of other living tissue, for endorsing binding between hard tissues, and/or for filling a mineralized wound cavity and/or tissue defect following from a procedure and/or trauma.

Abstract: The invention provides a method of treating T-cell mediated diseases and a method of inhibiting the activation of T-cells using certain diketopiperazines. The invention also provides methods of synthesizing diketopiperazines and pharmaceutical compositions comprising certain diketopiperazines. The invention further provides methods of making improved pharmaceutical compositions of proteins and peptides by either increasing or decreasing the content of diketopiperazines in the compositions and the resultant improved pharmaceutical compositions.

Abstract: The present invention relates to methods and compounds for treating specific early stage aspects and late stage aspects of diabetic nephropathy. Methods and compounds for treating various physiological features associated with early stage and with late stage diabetic nephropathy are also provided.

Abstract: A method of producing blood serum containing prophylactically or therapeutically active proteins, including obtaining blood from a patient, incubating the blood at a suitable temperature to induce production of prophylactically or therapeutically active proteins, and removing the prophylactically or therapeutically active proteins from the blood.

Abstract: Compositions and methods for delivering bioactive agents, such as vitamins, hormones, nutrients and drugs, by stabilizing and or solubilizing these agents in a polymer matrix. The carrier polymers can be used in drug delivery and are useful for delivery of small molecules.

Abstract: The disclosure is related generally to methods for testing mammary fluid (including milk) to establish or confirm the identity of the donor of the mammary fluid. Such methods are useful in the milk-bank business to improve safety.

Abstract: The present invention provides compositions comprising isolated human collagen, isolated human elastin and a pharmaceutically acceptable carrier wherein the human elastin is substantially insoluble in water with a molecular weight greater than 100 kDa. The present invention further provides methods and kits for soft tissue augmentation.

Abstract: A method includes obtaining a biological sample from a subject that does not display a symptom of Painful Bladder Syndrome (PBS). The method also includes analyzing the biological sample for a mutated form of NAD(P)H dehydrogenase [quinone], also known as Quinone Oxidoreductase 1, abbreviated NQO1, or a mutation of a NQO1 gene. The method also includes determining a risk of PBS for the subject based on analyzing the biological sample. In some methods, the mutation determined to present an increased risk is a cytosine to thymine nucleotide substitution at a position that leads to a proline to serine amino acid substitution at amino acid position 187 to produce a protein NQO1P187S. Another method includes selecting a subject that has above normal risk of Painful Bladder Syndrome (PBS) or is expressing a symptom of PBS, and treating the subject with a therapeutically effective amount of an antioxidant.

Abstract: Methods of treatment using IL-27 antagonists are provided. Such methods include, but are not limited to, methods of treating steroid-resistant conditions, such as asthma, chronic obstructive pulmonary disease (COPD), systemic lupus erythematosus (SLE), and inflammatory bowel disease. Such antagonists include, but are not limited to, antibodies that bind IL-27 and inhibit IL-27-mediated signaling (such as, for example, by blocking binding of IL-27 to its receptor); antibodies that bind the IL-27 receptor, alpha subunit, and inhibit IL-27-mediated signaling (such as, for example, by blocking binding of IL-27 to the receptor); and soluble forms of IL-27RA.

Abstract: Methods for diagnosing chronic diarrhea and other gastrointestinal conditions. In the methods, a sample of gastrointestinal secretions is obtained from a control group; or a group who has been diagnosed with either healthy gastrointestinal tracts or with a gastrointestinal condition, like chronic diarrhea. The control group samples are analyzed in any suitable manner to determine the levels of gastrointestinal secretions, including one or more autophagy-related proteins, cytokeratins, digestive enzymes, or other proteins. The results of the sample analysis are used to create a database containing profiles of normal and abnormal gastrointestinal secretions. As the database is created and specific secretion level abnormalities are identified, patients may be diagnosed with these abnormalities and be treated by adjusting the levels of specific secretions.

Abstract: Disclosed are methods of reducing the incidence of necrotizing enterocolitis in an infant, toddler, or child using nutritional compositions including human milk oligosaccharides. The nutritional compositions including the human milk oligosaccharides are effective in reducing inflammation and the incidence of inflammatory diseases.